I recently faced a question that I suspect many of us living with IBD encounter: can I switch from my current treatment delivery method to something else? In my case, after years on Remicade infusions, I was looking at the transition to Rinvoq pills in 2026. But the broader question applies to anyone weighing infusions versus self-injections versus oral medications.

Having lived with Crohn’s since 2002, I’ve been through this calculation more than once. The short answer is yes, you can often switch between delivery methods. The trade-offs are more nuanced than I initially realized.

The Delivery Method Landscape

When I started treatment in the early 2000s, the options were more limited. Infusions meant TNF inhibitors like Remicade or Inflectra. Self-injections opened up drugs like Humira, Cimzia, or Stelara. Pills were mostly limited to immunomodulators like methotrexate or 6-MP, with limited efficacy for many of us.

The landscape has expanded significantly. JAK inhibitors like Rinvoq and Xeljanz brought effective oral options for moderate to severe IBD. Newer biologics offer more injection choices. Each delivery method comes with distinct trade-offs — switching isn’t just about convenience.

What I Learned From My Own Switch

My transition from Remicade infusions to Rinvoq pills wasn’t primarily about delivery preference. It was about efficacy and side effects after years on the same biologic. But the delivery change was part of the decision calculus.

With Remicade, I had the predictable rhythm of infusion center visits every eight weeks. Three hours blocked out, but then I was done until the next cycle. The infusion center became familiar territory — same chairs, same nurses who knew my case, same IV access challenges every time.

Switching to a daily pill changed that completely. No more infusion appointments. Also no more built-in monitoring touchpoints. The convenience was real, but so was the shift in how I tracked my response to treatment.

Practical Considerations I Hadn’t Anticipated

The insurance approval process differed significantly between delivery methods. My infusion coverage had been straightforward for years, but switching to an oral JAK inhibitor required new prior authorization paperwork and different copay structures.

Travel became simpler in some ways — no more planning trips around infusion schedules. More complex in others. Pills require consistent timing and storage considerations that infusions don’t.

The monitoring requirements also shifted. Blood work frequency changed, and the parameters my gastroenterologist tracked were different between TNF inhibitors and JAK inhibitors.

The Trade-Offs Are Drug-Specific

After going through this transition, I realized that “switching delivery methods” isn’t really the right framing. You’re switching drugs, and each drug happens to come in a specific delivery format.

A TNF inhibitor like Humira delivers the same mechanism whether it’s the original injection or the newer citrate-free formulation. But switching from Remicade (infusion TNF inhibitor) to Rinvoq (oral JAK inhibitor) changes the entire mechanism of action — not just how I take the medication.

The delivery method affects adherence, lifestyle, and monitoring. The drug itself affects efficacy and side effect profile. I can’t separate those considerations.

Questions I Wish I’d Asked Earlier

Looking back on my decision process, there were questions I should have explored more systematically:

• How does insurance coverage differ between the delivery methods I’m considering?
• What are the monitoring requirements for each option, and how does that fit my schedule?
• If I travel frequently, how does each delivery method affect my ability to maintain consistent dosing?
• What happens if I need to switch back — is that path still available?
• How long does each option typically take to show efficacy, and what’s my backup plan during that window?

The last question turned out to be particularly important. Switching between drug classes often means a period of uncertainty about whether the new approach will work as well as what you’re leaving behind.

What This Means For My Current Management

I’m now several months into the Rinvoq transition, and the delivery method change has been the easiest part of the switch. Taking a daily pill fits my routine better than I expected. I don’t miss the infusion center visits.

I’ve also learned that delivery convenience shouldn’t drive treatment decisions. The drug’s efficacy for my specific disease pattern matters more than whether I prefer pills or injections. The delivery method is a quality-of-life factor, not a clinical outcomes factor.

If I had to make the decision again, I’d spend more time understanding the drug options within each delivery category rather than starting with delivery preference and working backward.

The Honest Assessment

Can you switch between delivery methods? Usually, yes. Should delivery method be your primary consideration? In my experience, no.

After two decades of treatment decisions, I’ve learned that the most convenient delivery method doesn’t matter if the drug doesn’t control my inflammation effectively. Among equally effective options, delivery method can be the deciding factor that makes long-term adherence more sustainable.

The trade-offs are individual. What worked for my lifestyle and disease pattern may not apply to someone else’s situation. Having gone through this decision process recently, I’d recommend focusing first on clinical efficacy data for your specific IBD presentation. Use delivery preference as a tiebreaker between similarly effective options.

That approach would have saved me some time second-guessing delivery logistics when the more important question was whether the new drug would work as well as what I was leaving behind.